IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 348 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $31,331,241 | +13.8% | 690,724 | +2.9% | 0.01% | +20.0% |
Q2 2023 | $27,534,330 | +17.0% | 671,078 | +1.9% | 0.01% | 0.0% |
Q1 2023 | $23,533,574 | -2.6% | 658,466 | +2.9% | 0.01% | 0.0% |
Q4 2022 | $24,161,054 | -12.4% | 639,689 | +2.6% | 0.01% | -16.7% |
Q3 2022 | $27,583,000 | +19.1% | 623,640 | -0.3% | 0.01% | +20.0% |
Q2 2022 | $23,155,000 | -3.6% | 625,472 | -3.6% | 0.01% | +25.0% |
Q1 2022 | $24,020,000 | +19.4% | 648,534 | -1.9% | 0.00% | +33.3% |
Q4 2021 | $20,112,000 | -8.5% | 660,890 | +0.8% | 0.00% | -25.0% |
Q3 2021 | $21,984,000 | -17.9% | 655,421 | -2.4% | 0.00% | -20.0% |
Q2 2021 | $26,789,000 | -29.2% | 671,573 | -20.2% | 0.01% | -28.6% |
Q1 2021 | $37,818,000 | -18.9% | 841,145 | +1.9% | 0.01% | -22.2% |
Q4 2020 | $46,656,000 | +18.2% | 825,174 | -0.8% | 0.01% | 0.0% |
Q3 2020 | $39,457,000 | -19.4% | 831,536 | +0.1% | 0.01% | -25.0% |
Q2 2020 | $48,972,000 | +24.0% | 830,597 | -0.6% | 0.01% | +9.1% |
Q1 2020 | $39,501,000 | -18.1% | 835,493 | +4.7% | 0.01% | 0.0% |
Q4 2019 | $48,225,000 | +0.7% | 798,287 | -0.1% | 0.01% | 0.0% |
Q3 2019 | $47,883,000 | -7.6% | 799,258 | -0.8% | 0.01% | -8.3% |
Q2 2019 | $51,794,000 | -2.2% | 805,897 | +23.5% | 0.01% | -7.7% |
Q1 2019 | $52,969,000 | +51.5% | 652,571 | +0.9% | 0.01% | +30.0% |
Q4 2018 | $34,966,000 | +5.9% | 646,790 | +1.0% | 0.01% | +25.0% |
Q3 2018 | $33,023,000 | +27.5% | 640,212 | +3.0% | 0.01% | +14.3% |
Q2 2018 | $25,903,000 | -2.1% | 621,643 | +3.5% | 0.01% | 0.0% |
Q1 2018 | $26,464,000 | -10.4% | 600,357 | +2.3% | 0.01% | 0.0% |
Q4 2017 | $29,525,000 | -1.5% | 586,982 | -0.7% | 0.01% | -12.5% |
Q3 2017 | $29,983,000 | -5.2% | 591,378 | -4.9% | 0.01% | -11.1% |
Q2 2017 | $31,631,000 | +36.4% | 621,816 | +7.8% | 0.01% | +28.6% |
Q1 2017 | $23,198,000 | -5.1% | 577,066 | +12.9% | 0.01% | 0.0% |
Q4 2016 | $24,445,000 | +31.2% | 511,088 | +0.5% | 0.01% | +16.7% |
Q3 2016 | $18,631,000 | +39.3% | 508,484 | -11.4% | 0.01% | +50.0% |
Q2 2016 | $13,371,000 | -40.0% | 574,085 | +4.4% | 0.00% | -42.9% |
Q1 2016 | $22,271,000 | -33.3% | 549,914 | +1.9% | 0.01% | -36.4% |
Q4 2015 | $33,407,000 | – | 539,426 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |